- All studies that fulfill the the federal definition of "research" and involve "human subjects" must be reviewed and approved by the IRB before any procedures are initiated.
- All research must be re-reviewed at least annually, and any changes to an approved protocol require prior review and approval.
- Adverse events, protocol violations, complaints, and other new information relevant to the research must be reported to the IRB in a timely fashion as each may alter the assessment of study risks or benefits.
At the time of submission, all studies are assigned a level of review based on risk, subject vulnerability, and to some extent the complexity of the proposed work.
- Studies that involve procedures that are "more than minimal risk" can only be approved by the convened IRB, also known as the Full Board.
- Minimal risk research and minor changes to approved research studies can be approved by the IRB Chair, or delegated to an IRB member for review and approval. This is referred to as expedited review.
- The PI-IRB utilizes a subcommittee review process for initial review of studies that require final review by the Full Board. The subcommittee also reviews and can approve other, minimal risk research.